FDA Approves SPIRONOLACTONE — Sun Pharmaceutical Industries, Inc.

Washington, D.C., December 13, 2023 – Sun Pharmaceutical Industries, Inc. announced that the FDA has approved a new generic version of spironolactone (SPIRONOLACTONE) oral tablet, broadening the competitive landscape for this widely used antihypertensive and potassium-sparing diuretic. This approval significantly increases availability and price accessibility for essential cardiovascular therapies, intensifying market share pressure on branded competitors and potentially expanding the patient pool for oral diuretic treatments.